AI Article Synopsis
- The study analyzed how high sensitivity cardiac troponin T (hs-cTnT) levels change in patients after they undergo cardioversion for atrial fibrillation/flutter.
- Researchers measured hs-cTnT alongside other biomarkers at various time points before and after the procedure, finding that while many patients initially showed elevated hs-cTnT levels, these did not significantly change over time.
- The findings suggest that the rise in hs-cTnT seen in patients with persistent atrial fibrillation/flutter is not a result of the cardioversion procedure itself, as levels tend to decrease gradually without further significant increases.
Article Abstract
Background: The kinetics of high sensitivity cardiac troponin T (hs-cTnT) levels after elective, biphasic, direct-current cardioversion for persistent atrial fibrillation/flutter remains unknown.
Methods: We examined hs-cTnT kinetics in 24 patients at baseline and at 2, 6 and 24 hours post-cardioversion, and again at 7 and 30 days. We also examined levels of creatine kinase, aspartate aminotransferase, lactate dehydrogenase, brain natriuretic peptide (BNP), and high sensitivity C-reactive protein (hs-CRP).
Results: Median (25th, 75th interquartiles) baseline hs-cTnT concentration was 19.8 (10.4, 35.2) ng/L with 14 patients presenting with levels above the 99th percentile (13 ng/L). Hs-cTnT levels did not change significantly over time although they tended to decrease by 30 days, 18.8 ng/L (12.5, 23.3). There was no significant rise in other markers of myocardial injury. Similarly, BNP and hs-CRP levels were elevated at baseline and tended to decrease over time.
Conclusions: Patients with persistent atrial fibrillation/flutter have elevated hs-cTnT levels, as part of a general rise in biomarkers such as BNP and hs-CRP, without a further rise after cardioversion. After cardioversion, there is a gradual non-significant decrease in biomarker levels over time, and thus a rise in hs-cTnT levels should not be attributed to cardioversion.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-Term Effect of Tafamidis on Clinical Parameters and Prognostic Predictors in Patients With Transthyretin Amyloid Cardiomyopathy.
Circ J
January 2025
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University.
Background: Accurate prediction of prognosis in transthyretin amyloid cardiomyopathy (ATTR-CM) is crucial for optimal treatment selection, including tafamidis, the only approved therapy for ATTR-CM. Although tafamidis has been proven to improve prognosis, the long-term serial changes in comprehensive parameters related to ATTR-CM, including cardiac biomarkers and imaging parameters, under tafamidis remain unknown.
Methods And Results: In this study, we used Cox regression analysis on data from 258 consecutive patients diagnosed with ATTR-CM at Kumamoto University to determine prognostic factors.
Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial.
J Gerontol A Biol Sci Med Sci
January 2025
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Background: The association between subclinical cardiovascular disease (CVD) and cognitive decline in hypertensive adults and the underlying brain pathologies remain unclear. It is also undetermined whether intensifying blood pressure (BP) treatment slows down cognitive decline associated with subclinical CVD.
Methods: We conducted a post hoc analysis of the Systolic Blood Pressure Intervention Trial.
Prognostic role of high-sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE-CS.
ESC Heart Fail
December 2024
Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Nankoku, Japan.
Aims: The prognostic role of high-sensitivity cardiac troponin T (hs-cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B-type natriuretic peptide (BNP).
Methods And Results: In this post-hoc analysis of the ILLUMINATE-CS (ILLUstration of the Management and prognosIs of JapaNese pATiEnts with Cardiac Sarcoidosis), which is a multicentre retrospective observational study, we analysed 103 patients (62.2 ± 10.
Predictive value of NT-proBNP for major adverse cardiovascular events within a 6-month period in patients with acute coronary syndrome.
Ir J Med Sci
December 2024
Department of Cardiology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Background: The role of NT-proBNP as a cardiac biomarker for predicting short-term major adverse cardiovascular events (MACEs) in acute coronary syndrome (ACS) remains unclear.
Aims: This study investigated the utility of the NT-proBNP level for predicting MACEs within a 6-month period in patients with ACS.
Methods: This prospective study included 241 consecutively enrolled adults with ACS between September 2023 and February 2024.
The impact of myocardial injury on outcomes in TAVI patients.
Clin Res Cardiol
December 2024
Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Article Synopsis
- The study investigates the impact of peri-procedural myocardial injury (PPMI) after transcatheter aortic valve implantation (TAVI) using the updated VARC-3 criteria compared to the previous VARC-2 criteria.
- High-sensitivity cardiac troponin T (hs-cTnT) levels were assessed pre- and post-procedure, with elevated baseline levels being significant predictors of all-cause mortality and major cardiac adverse events within one year post-TAVI.
- The findings indicate that VARC-3 criteria offered better prognostic insights regarding patient outcomes, with patients meeting VARC-3 criteria experiencing higher mortality rates than those meeting VARC-2 criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!